Medical technology company Paxman has received its first UK orders for the Paxman Neuropathy System, which aims to reduce nerve damage during chemotherapy.
Four systems will be installed in December at a private cancer care provider operating at four locations in the UK. The orders mark the company’s first commercial step beyond scalp cooling. No order value was provided.
